ENXTPA:SANPharmaceuticals
Does Positive AlphaMedix Phase II Data Reinforce the Bull Case for Sanofi (ENXTPA:SAN)?
Sanofi recently reported that its investigational therapy AlphaMedix™ (212Pb-DOTAMTATE) met all primary efficacy endpoints in a Phase II trial for patients with unresectable or metastatic SSTR-positive gastroenteropancreatic neuroendocrine tumors, demonstrating clinically meaningful response rates and prolonged clinical benefits in both PRRT-naive and PRRT-exposed groups.
This therapy, which leverages targeted alpha radiation for greater tumor selectivity and was granted US FDA Breakthrough...